Navigation Links
MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
Date:8/12/2008

SAN DIEGO, Aug. 12 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held immunotherapeutics discovery and development company focused on the development and commercialization of novel immunotherapies for the treatment of cancer, today announced the completion of two separate licensing agreements with the Memorial Sloan-Kettering Cancer Center's Sloan-Kettering Institute for Cancer Research (SKI).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080812/LATU515LOGO)

The first license agreement grants MabVax exclusive development and commercialization rights to multiple vaccines against recurrent cancer for six different types of cancer. MSKCC plans to initiate Phase I clinical trials in each of these types of cancer this year or early next year. Upon successful demonstration of immunogenicity and tolerability in the Phase I trials in sarcoma and small cell lung cancer, MabVax will initiate Phase II trials in these two cancer types. In addition to MabVax's efforts, MSKCC is planning to conduct Phase II trials with the licensed vaccines in ovarian and breast cancer. Pending successful outcomes, MabVax can assume responsibility for continued development and eventual commercialization of these vaccines.

The second license agreement grants MabVax exclusive rights to the use of the licensed vaccines and lymphocytes from successfully vaccinated clinical trial participants. MabVax plans to rescue antibodies from these patient samples to create a pipeline of fully human monoclonal antibody products against each of the vaccine targets expressed on the surface of the cancer cells. By rescuing antibodies from a selection of patients who generate a useful immune response, MabVax can select the optimal antibodies and develop them as either stand alone products or as combination products with the vaccines. MabVax has established a laboratory and office in the San Diego area to launch this effort.

"The completion of these two agreements establishes the scientific foundation of the company and firmly set us on a research and development pathway that we hope will address a significant unmet medical need by preventing recurrence in certain types of cancers and prolonging patient survival," said David Hansen, the company's President and Chief Executive Officer. Philip Livingston, M.D., the company's Chief Science Officer and co-founder of MabVax added, "Targeting residual circulating cancer cells and micrometastasis with passively administered or vaccine induced antibodies against multiple targets is an approach well suited to eradicating the cancer cells that cause metastatic disease. Our clinical trials over the next several years will tell us a great deal about the utility of this approach to treating cancer."

About MabVax Therapeutics, Inc.

MabVax was formed to commercialize the work of Dr. Phil Livingston and colleagues at Memorial Sloan-Kettering Cancer Center (MSKCC) who over the last 25 years have developed monovalent cancer vaccines against ten distinct antigenic targets on various types of cancer cells. These vaccines target gangliosides and other carbohydrate antigens that are the most extensively expressed antigenic targets on the cell surface of certain cancers. Vaccines, or passively administered antibodies developed from these vaccines, produced evidence demonstrating the prevention of tumor recurrence and prolonged survival in preclinical models and supporting data in early Phase I human clinical trials. The company is initially focused on developing polyvalent vaccines and a pipeline of fully human monoclonal antibodies to address a variety of cancers including sarcoma, small cell lung cancer, and melanoma. MabVax closed a Series A venture financing with GBP Capital in late February 2008.


'/>"/>
SOURCE MabVax Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017   The ... organization within medical affairs in the pharmaceutical industry ... the chair of a newly formed scientific advisory ... members to form the first ever medical affairs ... For more information about the ACMA, please visit  ...
(Date:3/24/2017)... , March 24, 2017 FinancialBuzz.com News Commentary   ... Medical cannabis products around the ... Inc., projects that the global medical cannabis market will reach a value ... is a major market for the new growing industry. By the end ... legally buy and sell medical cannabis. More conservative states like ...
(Date:3/24/2017)... India , March 24, 2017 A ... market has been growing rapidly as the global sales of Adcetris ... the growth in the antibody drug conjugates market is driven by ... of cancer and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... ... related services to families and business owners across eastern Michigan, is connecting with ... families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works to ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... (ONS) wanted to create a communications platform that positions them as the go-to ... and ONS reinvented their online publication as an always-on, always-fresh news, views and ...
(Date:3/24/2017)... ... 24, 2017 , ... The law firm of Enea, Scanlan & Sirignano, ... Westchester resident Lauren C. Enea has joined the firm as an associate attorney. Ms. ... practice in elder law, Medicaid planning and applications, and Wills, Trusts and Estates. ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located ... training and leads programs. , In February, 2017, Empower Brokerage introduced their new ... Partners is designed to teach how to maximize their sales efforts, as well ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... “End Time ... the salient events will interrelate. “End Time GPS” is the creation of published ... explosives expert while working on military munitions and space-vehicle projects. Now, at age ninety-one, ...
Breaking Medicine News(10 mins):